In Vitro Diagnostics (IVD) Quality Control

Global In Vitro Diagnostics (IVD) Quality Control Market to Reach US$1.2 Billion by 2032

The global market for In Vitro Diagnostics (IVD) Quality Control estimated at US$940.0 Million in the year 2025, is expected to reach US$1.2 Billion by 2032, growing at a CAGR of 4.1% over the analysis period 2025-2032. Clinical Chemistry, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$399.9 Million by the end of the analysis period. Growth in the Immunochemistry segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$290.8 Million While China is Forecast to Grow at 7.7% CAGR

The In Vitro Diagnostics (IVD) Quality Control market in the U.S. is estimated at US$290.8 Million in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$301.0 Million by the year 2032 trailing a CAGR of 7.7% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global In Vitro Diagnostics (IVD) Quality Control Market - Key Trends and Drivers Summarized

Why Is In Vitro Diagnostics (IVD) Quality Control Critical for Accurate Healthcare Diagnostics?

In Vitro Diagnostics (IVD) quality control plays a pivotal role in ensuring the accuracy, reliability, and consistency of diagnostic tests performed in laboratories. IVD tests are essential tools for diagnosing diseases, monitoring health conditions, and guiding treatment decisions. These tests include blood tests, molecular diagnostics, and microbiological assays, and they are used across various medical disciplines. Quality control (QC) measures in IVD are crucial because they help detect errors or inconsistencies in test results, which could otherwise lead to incorrect diagnoses or treatments. QC in IVD involves the regular calibration of diagnostic equipment, validation of test procedures, and monitoring of test performance through control samples, ensuring that the diagnostic outcomes are reliable and trustworthy.

How Are Technological Advancements Shaping the IVD Quality Control Market?

The IVD quality control market is undergoing significant transformation, thanks to advancements in technology. Automation in laboratories is increasingly being adopted, reducing human error and improving the accuracy of test results. The development of advanced control materials, including multi-analyte controls, has improved the ability to monitor multiple parameters simultaneously, ensuring comprehensive quality checks. Additionally, molecular diagnostics and point-of-care testing are growing rapidly, leading to the need for more sophisticated quality control processes that can handle the complexity and specificity of these newer technologies. Moreover, AI-driven data analysis is being integrated into IVD quality control systems, enabling laboratories to predict potential issues and adjust processes in real-time, further enhancing the reliability of diagnostics.

How Do Market Segments Define the Growth of the IVD Quality Control Market?

Product types include quality control materials, data management software, and instruments, with quality control materials holding the largest market share due to their wide applicability in various diagnostic tests. Applications of IVD quality control include clinical chemistry, immunoassay, hematology, and molecular diagnostics, with molecular diagnostics witnessing the fastest growth as personalized medicine and genetic testing gain traction. End-users include hospitals, clinical laboratories, and academic and research institutions, with clinical laboratories being the largest segment due to their high volume of testing and the critical need for consistent, reliable results. The market is also expanding globally, with North America and Europe leading in adoption, while the Asia-Pacific region is experiencing rapid growth due to increasing healthcare infrastructure investments.

What Factors Are Driving the Growth in the IVD Quality Control Market?

The growth in the IVD quality control market is driven by several factors, including the increasing demand for accurate diagnostics, the rising prevalence of chronic and infectious diseases, and stringent regulatory requirements for diagnostic accuracy. As healthcare systems strive to provide better outcomes, the need for precise diagnostic tools is paramount, pushing laboratories to invest in robust quality control measures. The increasing incidence of diseases such as cancer, diabetes, and cardiovascular conditions is also contributing to higher demand for diagnostic tests, thus driving the need for quality control in IVD. Furthermore, regulatory agencies such as the FDA and the European Medicines Agency (EMA) have implemented stricter guidelines, mandating rigorous QC practices to ensure patient safety and test reliability, further fueling market growth.

SCOPE OF STUDY:

The report analyzes the In Vitro Diagnostics (IVD) Quality Control market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Application (Clinical Chemistry, Immunochemistry, Molecular Diagnostics, Hematology, Other Applications); End-Use (Hospitals, Clinical Laboratories, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

• Abbott Laboratories
• Becton, Dickinson And Company (BD)
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Eurotrol B.V.
• F. Hoffmann -La Roche Ltd.
• Fortress Diagnostics Limited
• Helena Biosciences Europe
• Maine Molecular Quality Controls, Inc.
• Merck KGaA
• Omega Diagnostics Group Plc
• Ortho Clinical Diagnostics
• Randox Laboratories Ltd.
• Seracare Life Sciences Inc.
• Sero As
• Siemens Ag
• Sun Diagnostics, LLC.
• Technopath Clinical Diagnostics
• Thermo Fisher Scientific Inc.
• Zeptometrix Corporation

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more